Babel N, Eibl N, Ulrich C, Bold G, Sefrin A, Hammer M H, Rosenberger C, Reinke P
Department of Nephrology and Internal Intensive Care, Campus Virchow Clinic, Charité University Medicine, Berlin, Germany.
Transpl Infect Dis. 2008 Feb;10(1):59-62. doi: 10.1111/j.1399-3062.2007.00239.x. Epub 2007 Apr 11.
Kaposi's sarcoma (KS) is a vascular neoplasm typically observed in the immunocompromised patient populations, such as acquired immunodeficiency syndrome or transplant patients. KS can appear simultaneously at multiple sites as red to purple, maculo-papular or nodular cutaneous lesions sometimes showing a visceral extension. Sirolimus, an immunosuppressive agent with potent antitumor activity, has been effective in combating post-transplant KS. However, an aggressive regimen of immunosuppression for therapy of severe acute rejection episodes may abolish the antitumor effects of sirolimus. The following is a description of KS development under immunosuppressive therapy with sirolimus, and the successful treatment of KS lesions utilizing the topical application of imiquimod 5% cream, an immune response modifier.
卡波西肉瘤（KS）是一种血管性肿瘤，通常见于免疫功能低下的患者群体，如获得性免疫缺陷综合征患者或移植患者。KS可同时出现在多个部位，表现为红色至紫色的斑丘疹或结节性皮肤损害，有时还会出现内脏受累。西罗莫司是一种具有强大抗肿瘤活性的免疫抑制剂，已被证明对治疗移植后KS有效。然而，用于治疗严重急性排斥反应的积极免疫抑制方案可能会消除西罗莫司的抗肿瘤作用。以下是关于在使用西罗莫司进行免疫抑制治疗的情况下KS的发展情况，以及利用5%咪喹莫特乳膏（一种免疫反应调节剂）局部应用成功治疗KS皮损的描述。
